Orion sues Mylan in the U.S. to enforce its U.S. patents covering the proprietary drug Stalevo®
(Thomson Reuters ONE) -
Orion Corporation Stock Exchange Release 26 April 2012
at 19.25 EEST
Company states generic competition is not imminent based on this application.
Orion Corporation has filed a patent infringement lawsuit in the United States
to enforce Orion's U.S. patents No. 5,446,194, No. 6,500,867 and No. 6,797,732
covering Orion's product Stalevo® against Mylan Pharmaceuticals Inc. (Mylan).
Mylan seeks authorisation to produce and market generic tablets (strengths
12,5/50/200 mg; 18,75/75/200 mg; 25/100/200 mg; 31,25/125/200 mg; 37,5/150/200
mg and 50/200/200 mg) in the United States, with carbidopa, levodopa and
entacapone as active ingredients in the same proportion as in Orion's Stalevo®.
The product is an enhanced levodopa treatment originated by Orion Corporation
and marketed in the United States by its exclusive licensee, Novartis, for the
treatment of Parkinson's disease.
At this point, the Abbreviated New Drug Application (ANDA) review process is
just beginning in the United States and generic competition is not imminent
based on this application.
As reported on 26 March 2012, Orion Corporation was notified that Mylan
submitted an ANDA with the U.S. Food and Drug Administration (FDA) that included
a Paragraph IV challenge to the above mentioned patents.
By suing to enforce its patent within 45 days from receipt of the Paragraph IV
certification notice, Orion Corporation is entitled to an automatic stay
prohibiting the FDA from approving the applicant's ANDA for 30 months, or until
an earlier court decision adverse to Orion Corporation's above mentioned patents
in the infringement lawsuit. As such, the realisation of generic competition is
not imminent based on this application. Orion Corporation will defend the
intellectual property rights covering Stalevo.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO Senior VP, Corporate Functions
Contact person:
Olli Huotari, Senior VP, Corporate Functions
Phone +358 10 426 3054
Mobile +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler(®) pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1606390]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2012 - 12:25 Uhr
Sprache: Deutsch
News-ID 1107766
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Espoo
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 48 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion sues Mylan in the U.S. to enforce its U.S. patents covering the proprietary drug Stalevo®
"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
